US Stock MarketDetailed Quotes

OKUR OnKure Therapeutics

Watchlist
  • 18.420
  • -0.580-3.05%
Close Oct 11 16:00 ET
  • 19.340
  • +0.920+4.99%
Post 20:02 ET
244.99MMarket Cap-1938P/E (TTM)

OnKure Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
Total revenue
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
66.12%14.34M
12.33%9.83M
24.08%36.93M
8.63M
8.75M
29.77M
Selling and administrative expenses
220.63%3.59M
2.93%1.27M
23.44%4.82M
--1.12M
--1.23M
--3.9M
-General and administrative expense
220.63%3.59M
2.93%1.27M
23.44%4.82M
--1.12M
--1.23M
--3.9M
Research and development costs
43.09%10.75M
13.86%8.57M
24.18%32.12M
--7.51M
--7.52M
--25.86M
Operating profit
-66.12%-14.34M
-12.33%-9.83M
-24.08%-36.93M
-8.63M
-8.75M
-29.77M
Net non-operating interest income expense
-54.77%204K
304.11%295K
538.98%1.62M
451K
73K
254K
Non-operating interest income
-49.00%230K
304.11%295K
538.98%1.62M
--451K
--73K
--254K
Non-operating interest expense
--26K
----
----
--0
----
----
Other net income (expense)
Income before tax
-72.79%-14.14M
-9.87%-9.54M
-19.65%-35.31M
-8.18M
-8.68M
-29.51M
Income tax
Net income
-72.79%-14.14M
-9.87%-9.54M
-19.65%-35.31M
-8.18M
-8.68M
-29.51M
Net income continuous Operations
-72.79%-14.14M
-9.87%-9.54M
-19.65%-35.31M
---8.18M
---8.68M
---29.51M
Minority interest income
Net income attributable to the parent company
-72.79%-14.14M
-9.87%-9.54M
-19.65%-35.31M
-8.18M
-8.68M
-29.51M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-72.79%-14.14M
-9.87%-9.54M
-19.65%-35.31M
-8.18M
-8.68M
-29.51M
Basic earnings per share
-72.79%-1.0599
-9.87%-0.7149
-19.65%-2.6471
-0.6134
-0.6506
-2.2124
Diluted earnings per share
-72.79%-1.0599
-9.87%-0.7149
-19.65%-2.6471
-0.6134
-0.6506
-2.2124
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022
Total revenue 000000
Operating revenue --0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 66.12%14.34M12.33%9.83M24.08%36.93M8.63M8.75M29.77M
Selling and administrative expenses 220.63%3.59M2.93%1.27M23.44%4.82M--1.12M--1.23M--3.9M
-General and administrative expense 220.63%3.59M2.93%1.27M23.44%4.82M--1.12M--1.23M--3.9M
Research and development costs 43.09%10.75M13.86%8.57M24.18%32.12M--7.51M--7.52M--25.86M
Operating profit -66.12%-14.34M-12.33%-9.83M-24.08%-36.93M-8.63M-8.75M-29.77M
Net non-operating interest income expense -54.77%204K304.11%295K538.98%1.62M451K73K254K
Non-operating interest income -49.00%230K304.11%295K538.98%1.62M--451K--73K--254K
Non-operating interest expense --26K----------0--------
Other net income (expense)
Income before tax -72.79%-14.14M-9.87%-9.54M-19.65%-35.31M-8.18M-8.68M-29.51M
Income tax
Net income -72.79%-14.14M-9.87%-9.54M-19.65%-35.31M-8.18M-8.68M-29.51M
Net income continuous Operations -72.79%-14.14M-9.87%-9.54M-19.65%-35.31M---8.18M---8.68M---29.51M
Minority interest income
Net income attributable to the parent company -72.79%-14.14M-9.87%-9.54M-19.65%-35.31M-8.18M-8.68M-29.51M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -72.79%-14.14M-9.87%-9.54M-19.65%-35.31M-8.18M-8.68M-29.51M
Basic earnings per share -72.79%-1.0599-9.87%-0.7149-19.65%-2.6471-0.6134-0.6506-2.2124
Diluted earnings per share -72.79%-1.0599-9.87%-0.7149-19.65%-2.6471-0.6134-0.6506-2.2124
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data